EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Is 10 milligrams selegiline essential as an adjunct therapy for the symptomatic treatment of Parkinson's disease?



Is 10 milligrams selegiline essential as an adjunct therapy for the symptomatic treatment of Parkinson's disease?



Therapeutic Drug Monitoring 20(6): 717-721



Selegiline is used as an adjunct to levodopa in the symptomatic treatment of Parkinson's disease (PD). The normal daily dose of selegiline is 10 mg administered orally. This study, based on monoamine oxidase-B (MAO-B) inhibition, investigates whether a reduction in selegiline dose can provide the same beneficial effects seen with a 10-mg dose. The inhibition of platelet MAO-B activity against multiple dosing of selegiline (2.5, 5, and 7.5 mg) was predicted from the data obtained from literature (0.5, 1.0, 1.5, and 10 mg). A pharmacokinetic-pharmacodynamic model for selegiline was also developed. The data suggested that by 96 hours (four doses) the inhibition of platelet MAO-B activity is approximately 95% after a daily dose of 2.5 mg selegiline, whereas it takes only 48 hours (two doses) for doses of 5 mg and 7.5 mg to achieve this degree of inhibition. The pharmacokinetic-pharmacodynamic model was best described by a sigmoidal Emax model with an effect compartment. Based on the inhibition of MAO-B activity, a reduction in daily oral dose of selegiline appears possible without compromising the therapeutic effect. Therefore, lower doses of selegiline should be tested in clinical trials.

(PDF emailed within 1 workday: $29.90)

Accession: 010885910

Download citation: RISBibTeXText

PMID: 9853994



Related references

Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients. Archives of Neurology 46(12): 1280-1283, 1989

Selegiline as an adjunct to conventional l dopa therapy in parkinson's disease experience with this type b monoamine oxidase inhibitor in 200 patients. Archives of Neurology 46(12): 1280-1283, 1989

Early combination of selegiline and low dose l dopa as initial symptomatic therapy in parkinson's disease experience in 26 patients receiving combined therapy for 26 months. Archives of Neurology 48(1): 31-34, 1991

Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months. Archives of Neurology 48(1): 31-34, 1991

Selegiline in Parkinson's disease; symptomatic or causal effect?. Nederlands Tijdschrift Voor Geneeskunde 136(32): 1544-1547, 1992

Selegiline and Parkinson's disease. Protective and symptomatic considerations. Drugs 39(5): 646-651, 1990

Selegiline and the Treatment of Parkinson's Disease: How patients can benefit from drug therapy. Canadian Family Physician Medecin de Famille Canadien 37: 1231-1236, 1991

Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?. Neurology 42(4 Suppl 4): 13-26; Discussion 41-8, 1992

Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs & Aging 1(3): 228-248, 1991

Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. Current Medical Research and Opinion 23(4): 741-750, 2007

Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study. Journal of Neural Transmission 108(2): 215-219, 2001

Selegiline in the therapy of Parkinson's disease. Vojnosanitetski Pregled 49(4): 357-368, 1992

Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. Bmj 316(7139): 1191-1196, 1998

Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. Parkinsonism & Related Disorders 17(2): 117-118, 2011